CicloMed aims to improve life for cancer patients
Bladder cancer takes 165,000 lives a year worldwide – and also burdens survivors with a lifetime of monitoring, surgical procedures and chemotherapy treatments. Current standards of care for bladder cancer are difficult for patients, and recurrences are expensive for healthcare.
CicloMed LLC, a developmental-stage pharmaceutical company with a collaborative team of experts in drug development and cancer treatment, aims to change the narrative.
CicloMed is developing a novel drug candidate known as Ciclopirox Prodrug, one of only a few new agents in decades targeting bladder cancer, potentially in its earlier and later stages (non-muscle invasive and muscle invasive bladder cancers).
Ciclopirox Prodrug is currently being evaluated in a Phase I first-in-human clinical trial in cancer patients. The goal of this trial is to characterize the safety, dose tolerance, pharmacokinetics and pharmacodynamics of Ciclopirox Prodrug in patients with advanced solid tumors. While still in early stages of development, this new agent holds potential to transform treatment of bladder cancer, improving outcomes for patients and reducing burdensome recurrences.
Our paradigm-changing approach to bladder cancer springs from a productive public-private partnership with The University of Kansas Cancer Center. Scientists at KU discovered Ciclopirox Prodrug and demonstrated its potential in preclinical models as an anticancer agent. Ciclopirox Prodrug for Injection was licensed to CicloMed in 2015. Our team is collaborating with experts across the country to develop this novel drug for the treatment of muscle invasive and non-muscle invasive bladder cancer.
CicloMed is a portfolio company of BioNovus Innovations LLC, a unique venture formed to invest in individuals and organizations that are transforming healthcare. BioNovus is charting a new path with the financial investment and commitment to bring novel solutions to reality.